Brief Summary
This phase 1/2 first-in-human study is designed to test the safety and efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a single agent and in combination with other therapies in HLA-A*02:01-positive participants with selected advancedat a late stage, far along cancers.
Intervention / Treatment
- Drug: IMC-R117C
- Drug: Chemotherapya cancer treatment that uses drugs to kill or slow the growth of cancer cells, while minimising damage to healthy cells drug
- Drug: Chemotherapy drug
- Drug: Kinase inhibitor
- Drug: Antiangiogenic Agent
- Drug: Monoclonal antibodya protein made by the immune system to fight against harmful substances (antigens), such as bacteria or viruses
Inclusion Criteria:
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status score of 0 or 1
- HLA-A*02:01-positive
- Histologically confirmed advanced colorectalrelating to the colon or rectum in the large bowel/intestine, esophageal, gastric, or ovarian carcinomacancer arising from tissues that line organs
- Archived or fresh tumor tissuea group of cells that work together to perform a function sample that must be confirmed as adequate
- Evaluable/Measurable disease per RECIST 1.1
- Previously received applicable standard treatments
- Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control